China SFDA Calls For Release Of Materials To Ease Hemophilia Treatment Shortage (China)
This article was originally published in PharmAsia News
Executive Summary
China's State FDA says it has asked four blood-products companies in the country to release the raw materials used to make the clotting factor VIII to help eliminate a shortage of the materials needed to treat hemophilia. The agency sent the firms a notice seeking cryoprecipitate, a frozen blood product produced from plasma, to make them available to the three companies that produce factor VIII. The shortage was caused in part to a 50 percent drop in the plasma supply last year. (Click here for more )
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.